While increasing the expression/activity of MKP-2 to sensitize cells to tamoxifen therapy is not a viable therapeutic strategy at this time, our results support the importance of continuing to develop clinically effective ways to reduce ERK activity in breast cancer cells. Here, DUSP4 is linked to breast carcinoma.